{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-066091","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2025-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.353431+00:00","generated_at":"2026-05-18T09:20:28.733922+00:00","sec_items":["2.05","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Century Therapeutics cuts 51% of workforce; CFO and CDO to depart","bullets":["Board approved reduction in force of ~51% of employees; expects $3.7M in severance costs.","CFO Morgan Conn to depart effective July 11; SVP Finance Douglas Carr named interim principal financial officer.","Chief Development Officer Adrienne Farid to depart effective July 31.","Workforce reduction substantially complete by end of Q3 2025; company focusing on highest-potential programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-066091","json":"https://secwatch.observer/filing/0001104659-25-066091.json","markdown":"https://secwatch.observer/filing/0001104659-25-066091.md","text":"https://secwatch.observer/filing/0001104659-25-066091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465925066091/0001104659-25-066091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465925066091/tm2519717d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:20:28.733922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe5129d42654a0addef823f2cd316f53e060baf7","claim":"Century Therapeutics, Inc. announced a restructuring with charges of approximately $3.7 million (approximately 51%).","evidence_excerpt":"On July 1, 2025, the Board of Directors (the “ Board ”) of Century Therapeutics, Inc. (the “ Company ”) approved a reduction in force as part of a broader effort to right size the organization to focus on programs with the highest potential for transformational value. The Company expects to implement a net reduction of its employee headcount by approximately 51% (the “ RIF ”). As part of the RIF, the Company estimates that it will incur charges of approximately $3.7 million for severance and other employee termination-related costs.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465925066091/0001104659-25-066091-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.7 million"},{"label":"Headcount","value":"approximately 51%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}